JP2013539857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013539857A5 JP2013539857A5 JP2013528723A JP2013528723A JP2013539857A5 JP 2013539857 A5 JP2013539857 A5 JP 2013539857A5 JP 2013528723 A JP2013528723 A JP 2013528723A JP 2013528723 A JP2013528723 A JP 2013528723A JP 2013539857 A5 JP2013539857 A5 JP 2013539857A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- treatment
- mdsc
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 31
- 206010028980 Neoplasm Diseases 0.000 claims 29
- 201000011510 cancer Diseases 0.000 claims 28
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 6
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 5
- 229940022399 cancer vaccine Drugs 0.000 claims 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 5
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 4
- 102100022338 Integrin alpha-M Human genes 0.000 claims 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- 238000009007 Diagnostic Kit Methods 0.000 claims 3
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 3
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 3
- 102100025390 Integrin beta-2 Human genes 0.000 claims 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 3
- 208000009956 adenocarcinoma Diseases 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 239000013610 patient sample Substances 0.000 claims 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- 102100035793 CD83 antigen Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- -1 IL4Ra Proteins 0.000 claims 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 210000005008 immunosuppressive cell Anatomy 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- 229960001796 sunitinib Drugs 0.000 claims 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101150008417 LIN gene Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38478410P | 2010-09-21 | 2010-09-21 | |
| GB1015765.9 | 2010-09-21 | ||
| US61/384,784 | 2010-09-21 | ||
| GBGB1015765.9A GB201015765D0 (en) | 2010-09-21 | 2010-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
| PCT/EP2011/066397 WO2012038463A2 (en) | 2010-09-21 | 2011-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013539857A JP2013539857A (ja) | 2013-10-28 |
| JP2013539857A5 true JP2013539857A5 (enExample) | 2014-10-30 |
| JP5970459B2 JP5970459B2 (ja) | 2016-08-17 |
Family
ID=43065538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013528723A Expired - Fee Related JP5970459B2 (ja) | 2010-09-21 | 2011-09-21 | がん診断用バイオマーカーに対する骨髄細胞の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9671404B2 (enExample) |
| EP (1) | EP2619585B1 (enExample) |
| JP (1) | JP5970459B2 (enExample) |
| KR (1) | KR20130137635A (enExample) |
| CN (1) | CN103180739B (enExample) |
| CA (1) | CA2811070A1 (enExample) |
| EA (1) | EA201390413A1 (enExample) |
| GB (1) | GB201015765D0 (enExample) |
| SG (2) | SG188543A1 (enExample) |
| WO (1) | WO2012038463A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP3682896A1 (en) * | 2011-04-28 | 2020-07-22 | University of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013169913A1 (en) * | 2012-05-08 | 2013-11-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Predictors of patient response to interferon-a therapy |
| US20160030558A1 (en) * | 2013-03-13 | 2016-02-04 | Health Research, Inc. | Enhancement of vaccines |
| CN103743907B (zh) * | 2013-07-24 | 2015-04-15 | 北京大学人民医院 | 测定造血干细胞移植后患者骨髓微循环环境评测的试剂盒、系统及方法 |
| WO2015048748A1 (en) * | 2013-09-30 | 2015-04-02 | Board Of Regents, The University Of Texas System | Myeloid-derived suppressor cell-specific peptides for diagnostic and therapeutic use |
| CN103626846B (zh) * | 2013-11-08 | 2016-06-01 | 上海交通大学 | 与MDSCs特异性结合的配体多肽及药物输送系统 |
| EP3012271A1 (en) * | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| WO2016210241A1 (en) * | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
| MX2018002640A (es) * | 2015-09-02 | 2018-06-20 | Syndax Pharmaceuticals Inc | Seleccion de pacientes para la terapia de combinacion. |
| KR102883915B1 (ko) | 2015-12-16 | 2025-11-18 | 시애틀 프로젝트 코포레이션 | 신생항원 동정, 제조, 및 용도 |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| EP4438626A3 (en) | 2016-04-14 | 2024-12-04 | OSE Immunotherapeutics | New anti-sirpa antibodies and their therapeutic applications |
| NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| CN107102127B (zh) * | 2017-04-07 | 2019-08-06 | 东北师范大学 | 一种人体外周血中单核样髓源抑制细胞的检测方法 |
| AU2018269039B2 (en) | 2017-05-19 | 2025-05-15 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| WO2018221820A1 (ko) * | 2017-06-02 | 2018-12-06 | 이종균 | 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트 |
| JP7227237B2 (ja) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | ホットスポットを利用した新生抗原の特定 |
| US11713356B2 (en) | 2017-10-13 | 2023-08-01 | Ose Immunotherapeutics | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| KR102216725B1 (ko) * | 2017-12-29 | 2021-02-17 | 연세대학교 산학협력단 | 면역 항암 요법에 대한 치료 반응 예측 방법 |
| CA3091468A1 (en) | 2018-03-13 | 2019-09-19 | Ose Immunotherapeutics | Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies |
| WO2019217484A1 (en) | 2018-05-07 | 2019-11-14 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| CN110501483B (zh) * | 2019-07-25 | 2020-12-29 | 同济大学 | 一种中草药活性的检测方法 |
| TR202003833A1 (tr) | 2020-03-12 | 2021-09-21 | Hacettepe Ueniversitesi Rektoerluek | Mi̇yeloi̇d kökenli̇ baskilayici hücrelere özgü bi̇yobeli̇rteç paneli̇ |
| EP4347653A1 (en) | 2021-06-04 | 2024-04-10 | Boehringer Ingelheim International GmbH | Anti-sirp-alpha antibodies |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
| CN117030580B (zh) * | 2023-09-15 | 2024-07-16 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | LDNs在坏死性小肠结肠炎诊断中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US20040136973A1 (en) * | 2002-11-07 | 2004-07-15 | Eliezer Huberman | Human stem cell materials and methods |
| US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| GB0820698D0 (en) * | 2008-11-12 | 2008-12-17 | Ludwig Inst Cancer Res | Uses of immunomodulators |
-
2010
- 2010-09-21 GB GBGB1015765.9A patent/GB201015765D0/en not_active Ceased
-
2011
- 2011-09-21 SG SG2013018973A patent/SG188543A1/en unknown
- 2011-09-21 SG SG10201510470WA patent/SG10201510470WA/en unknown
- 2011-09-21 KR KR1020137010009A patent/KR20130137635A/ko not_active Withdrawn
- 2011-09-21 CA CA2811070A patent/CA2811070A1/en not_active Abandoned
- 2011-09-21 CN CN201180045200.3A patent/CN103180739B/zh not_active Expired - Fee Related
- 2011-09-21 JP JP2013528723A patent/JP5970459B2/ja not_active Expired - Fee Related
- 2011-09-21 US US13/239,011 patent/US9671404B2/en not_active Expired - Fee Related
- 2011-09-21 EA EA201390413A patent/EA201390413A1/ru unknown
- 2011-09-21 WO PCT/EP2011/066397 patent/WO2012038463A2/en not_active Ceased
- 2011-09-21 EP EP11758209.8A patent/EP2619585B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013539857A5 (enExample) | ||
| Chen et al. | Dual TGF‐β and PD‐1 blockade synergistically enhances MAGE‐A3‐specific CD8+ T cell response in esophageal squamous cell carcinoma | |
| Chow et al. | Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy | |
| Tumino et al. | Polymorphonuclear myeloid-derived suppressor cells are abundant in peripheral blood of cancer patients and suppress natural killer cell anti-tumor activity | |
| Taylor et al. | Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer | |
| Solito et al. | Myeloid‐derived suppressor cell heterogeneity in human cancers | |
| De Monte et al. | Basophil recruitment into tumor-draining lymph nodes correlates with Th2 inflammation and reduced survival in pancreatic cancer patients | |
| Yanagisawa et al. | WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study | |
| Xu et al. | Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma | |
| Vujanovic et al. | CD56dim CD16− natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-α | |
| Kalathil et al. | Higher frequencies of GARP+ CTLA-4+ Foxp3+ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality | |
| Liotta et al. | Frequency of regulatory T cells in peripheral blood and in tumour‐infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma | |
| Tarek et al. | Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment | |
| Le et al. | Follicular B lymphomas generate regulatory T cells via the ICOS/ICOSL pathway and are susceptible to treatment by anti-ICOS/ICOSL therapy | |
| Avril et al. | Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2, 3-dioxygenase (IDO) on tumour-specific T cell functions | |
| KR20130137635A (ko) | 암의 진단을 위한 골수 세포 생체지표의 용도 | |
| Kakita et al. | Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25− FOXP3− T cells | |
| Atreya et al. | The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer | |
| Nair et al. | Immunologic targeting of FOXP3 in inflammatory breast cancer cells | |
| Liang et al. | FOXA1+ regulatory T cells: A novel T cell subset that suppresses antitumor immunity in lung cancer | |
| Heidari et al. | Effects of indoleamine 2, 3‐dioxygenase (IDO) silencing on immunomodulatory function and cancer‐promoting characteristic of adipose‐derived mesenchymal stem cells (ASCs) | |
| Ryuge et al. | Prognostic impact of nestin expression in resected large cell neuroendocrine carcinoma of the lung | |
| Beyer et al. | Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3 | |
| Hirooka et al. | The role of circulating dendritic cells in patients with unresectable pancreatic cancer | |
| Curran et al. | PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma |